Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of...

Area of Science:

• Immunology
• Biochemistry
• Therapeutics

Background:

• Complement system dysregulation contributes to inflammatory disease pathogenesis.
• Inhibiting the complement system is a viable therapeutic strategy.
• Mannose-binding lectin/ficolin/collectin-associated protein-1 (MAP-1) regulates the lectin pathway (LP).
• Complement receptor 1 (CD35) and decay-accelerating factor (CD55) are membrane regulators of C3.

Purpose of the Study:

• To develop novel soluble chimeric inhibitors targeting the complement cascade.
• To modulate complement activation at multiple stages using fusion proteins.
• To investigate the therapeutic potential of MAP-1 fused with CD35 or CD55 domains.

Main Methods:

• Constructed 2 novel soluble chimeric inhibitors by fusing MAP-1 with CD35 domains (CD35^1-3) or CD55 domains (CD55^1-4).
• Assessed biologic properties of the fusion proteins.
• Evaluated inhibitory efficacy in functional complement activation assays, focusing on C3 and terminal complement complex formation.
• Tested enhancement of activity with recombinant LP recognition molecules (MBL, ficolin-3).

Main Results:

• The fusion constructs exhibited biologic properties similar to their parent molecules.
• Constructs efficiently inhibited LP activation at the C3 level and terminal complement complex formation.
• Coincubation with MBL and ficolin-3 enhanced the inhibitory activity of the fusion proteins.
• Targeting inflammation sites with MAP-1 fusion proteins and LP recognition molecules showed therapeutic promise.

Conclusions:

• Novel MAP-1:CD35 and MAP-1:CD55 fusion proteins effectively modulate the complement cascade.
• These fusion proteins offer a targeted therapeutic approach for complement-related inflammatory pathologies.
• Combining these inhibitors with LP recognition molecules presents a novel strategy for complement modulation.